NIKKEI 225
37,628.48 -831.60 (-2.16%) HANG SENG
17,235.82 +34.55 (+0.20%) CRUDE OIL
82.94 +0.13 (+0.16%) GOLD FUTURES
2,331.20 -7.20 (-0.31%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,475.16 -1,922.61 (-3.60%)
PTC Therapeutics, Inc. (PTCT)
After hours:
| Previous close | 25.41 |
| Open | 25.79 |
| Bid | 25.16 x 300 |
| Ask | 25.24 x 300 |
| Day's range | 24.85 - 25.99 |
| 52-week range | 17.53 - 59.84 |
| Volume | |
| Avg. volume | 898,040 |
| Market cap | 1.931B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 19, 2024, the company approved non-statutory stock options to purchase an aggregate of 8,090 shares of its common stock and 8,290 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to six new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.
- PR Newswire
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2024 financial results and provide an update on the company's business and outlook on Thursday, April 25, at 4:30 p.m. ET.
- PR Newswire
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin MAA to the European Medicines Agency. The MAA submission is for the treatment of pediatric and adult patients with PKU, including the full spectrum of disease subtypes.
